Zoetis Inc. (NYSE:ZTS) Shares Sold by Asset Dedication LLC

Asset Dedication LLC trimmed its holdings in Zoetis Inc. (NYSE:ZTSFree Report) by 76.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 302 shares of the company’s stock after selling 994 shares during the quarter. Asset Dedication LLC’s holdings in Zoetis were worth $49,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Pensionfund Sabic increased its stake in Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after purchasing an additional 4,000 shares during the period. PFW Advisors LLC purchased a new position in shares of Zoetis during the fourth quarter worth about $1,764,000. JPMorgan Chase & Co. increased its position in Zoetis by 10.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after acquiring an additional 279,092 shares during the period. Simplify Asset Management Inc. purchased a new stake in Zoetis during the 3rd quarter valued at approximately $11,684,000. Finally, Nordea Investment Management AB lifted its position in Zoetis by 38.3% during the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after acquiring an additional 572,511 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $172.61 on Friday. The stock has a fifty day moving average price of $169.82 and a 200 day moving average price of $179.59. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a market cap of $77.88 billion, a PE ratio of 32.45, a P/E/G ratio of 2.57 and a beta of 0.89. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53.

Zoetis (NYSE:ZTSGet Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.36 EPS. Sell-side analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.16%. This is a boost from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Analyst Upgrades and Downgrades

ZTS has been the subject of several analyst reports. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. raised their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Morgan Stanley reduced their price objective on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, UBS Group assumed coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $215.00.

Check Out Our Latest Research Report on Zoetis

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Read More

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.